← Leaderboards

Mark J Ratain

University Of Chicago

Google Scholar ↗PubMed ↗ORCID ↗

$26,736,475

Attributed

$30,552,351

Total exposure

19

Grants

9

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.7M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$69,557,775 · 20

By mechanism

U01$58,220,954 · 8

T32$8,302,069 · 1

P30$1,011,269 · 4

UM1$986,528 · 1

U10$590,862 · 1

M01$446,093 · 5

Top collaborators

Most similar at University Of Chicago

Same institution · by research overlap

Chuan He$53,119,947
M Eileen Dolan$15,055,139
Richard L Schilsky$24,946,699
Gayle E Woloschak$21,789,151
Bakhtiar Yamini$5,001,614

Others in their field

Top investigators on “Clinical Research”

David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
Sonia M Thomas · Research Triangle Institute$700,865,642
Jeffrey P Krischer · University Of South Florida$611,867,176
Barton F Haynes · Duke University$538,862,577

Research focus

Clinical ResearchPharmacogeneticsAntineoplasticsResearch PersonnelPharmaceutical PreparationsHuman SubjectAntineoplastic AgentsBaseGenetic PolymorphismNeoplasm /Cancer ChemotherapyClinical TrialsResponseHuman Therapy EvaluationCooperative StudyPharmacokineticsGenotypeToxic EffectUniversitiesCollaborationsProgramsResourcesPharmacogenomicsIrinotecanGenetic

Grant awards (120)

Clinical Therapeutics$573,622

T32 · FY2025 · GM

Clinical Therapeutics$301,147

T32 · FY2024 · GM

Clinical Therapeutics$632,158

T32 · FY2023 · GM

Clinical Therapeutics$615,118

T32 · FY2022 · GM

Pharmacology$83,974

P30 · FY2022 · CA · contact PI

Clinical Therapeutics$586,974

T32 · FY2021 · GM

Pharmacology$84,464

P30 · FY2021 · CA · contact PI

Clinical Therapeutics$555,779

T32 · FY2020 · GM

Pharmacology$84,464

P30 · FY2020 · CA · contact PI

Pharmacology$4,735

P30 · FY2020 · CA · contact PI

Clinical Therapeutics$315,158

T32 · FY2019 · GM · contact PI

Pharmacology$84,464

P30 · FY2019 · CA · contact PI

Clinical Therapeutics$529,850

T32 · FY2018 · GM · contact PI

Pharmacology$84,387

P30 · FY2018 · CA · contact PI

Pharmacology$2,728

P30 · FY2018 · CA · contact PI

Pharmacology$2,621

P30 · FY2018 · CA · contact PI

Clinical Therapeutics$508,721

T32 · FY2017 · GM · contact PI

Clinical Therapeutics$423,831

T32 · FY2016 · GM · contact PI

Experimental Therapeutics: Clinical Trials Network with Phase I Emphasis$476,528

UM1 · FY2015 · CA · contact PI

Clinical Therapeutics$410,223

T32 · FY2015 · GM · contact PI

PAAR-Pharmacogenomics of Anticancer Agents Research Group$1,849,572

U01 · FY2014 · GM · contact PI

Parent Project - Main Theme (MAIN)$980,063

U01 · FY2014 · GM · contact PI

Experimental Therapeutics: Clinical Trials Network with Phase I Emphasis$510,000

UM1 · FY2014 · CA · contact PI

CORE IV - Management and Administrative CORE (MAC)$196,793

U01 · FY2014 · GM · contact PI

PAAR-Pharmacogenomics of Anticancer Agents Research Group$100,000

U01 · FY2014 · GM · contact PI

Clinical Therapeutics$89,360

T32 · FY2014 · GM · contact PI

CORE V - Liver Tissue CORE (LTC)$47,824

U01 · FY2014 · GM · contact PI

PAAR-Pharmacogenomics of Anticancer Agents Research Group$1,826,851

U01 · FY2013 · GM · contact PI

Parent Project - Main Theme (MAIN)$952,700

U01 · FY2013 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$780,770

U01 · FY2013 · CA · contact PI

Clinical Therapeutics$248,843

T32 · FY2013 · GM · contact PI

CORE IV - Management and Administrative CORE (MAC)$198,370

U01 · FY2013 · GM · contact PI

CORE V - Liver Tissue CORE (LTC)$47,214

U01 · FY2013 · GM · contact PI

PAAR-Pharmacogenomics of Anticancer Agents Research Group$1,979,869

U01 · FY2012 · GM · contact PI

Parent Project - Main Theme (MAIN)$992,348

U01 · FY2012 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$780,769

U01 · FY2012 · CA · contact PI

Clinical Therapeutics$265,490

T32 · FY2012 · GM · contact PI

CORE IV - Management and Administrative CORE (MAC)$207,581

U01 · FY2012 · GM · contact PI

CORE V - Liver Tissue CORE (LTC)$47,965

U01 · FY2012 · GM · contact PI

PAAR-Pharmacogenomics of Anticancer Agents Research Group$2,022,046

U01 · FY2011 · GM · contact PI

Parent Project - Main Theme (MAIN)$1,065,585

U01 · FY2011 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$780,771

U01 · FY2011 · CA · contact PI

Clinical Therapeutics$245,220

T32 · FY2011 · GM · contact PI

CORE IV - Management and Administrative CORE (MAC)$209,615

U01 · FY2011 · GM · contact PI

CORE V - Liver Tissue CORE (LTC)$47,025

U01 · FY2011 · GM · contact PI

PAAR-Pharmacogenomics of Anticancer Agents Research Group$2,104,000

U01 · FY2010 · GM · contact PI

Parent Project - Main Theme (MAIN)$1,062,196

U01 · FY2010 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$804,916

U01 · FY2010 · CA · contact PI

Clinical Therapeutics$252,621

T32 · FY2010 · GM · contact PI

CORE IV - Management and Administrative CORE (MAC)$218,085

U01 · FY2010 · GM · contact PI

CORE V - Liver Tissue CORE (LTC)$61,500

U01 · FY2010 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$2,736,772

U01 · FY2009 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$782,412

U01 · FY2009 · CA · contact PI

Colorectal Cancer$315,682

U01 · FY2009 · GM · contact PI

Clinical Therapeutics$149,935

T32 · FY2009 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$60,870

U01 · FY2009 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$2,781,123

U01 · FY2008 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$766,143

U01 · FY2008 · CA · contact PI

Colorectal Cancer$320,795

U01 · FY2008 · GM · contact PI

Clinical Therapeutics$196,140

T32 · FY2008 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$2,908,227

U01 · FY2007 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$624,589

U01 · FY2007 · CA · contact PI

Colorectal Cancer$340,689

U01 · FY2007 · GM · contact PI

Clinical Therapeutics$78,422

T32 · FY2007 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$45,360

U01 · FY2007 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$2,902,685

U01 · FY2006 · GM · contact PI

Phase I Clinical Trials of Anti-Cancer Agents$627,303

U01 · FY2006 · CA · contact PI

Colorectal Cancer$373,924

U01 · FY2006 · GM · contact PI

SORAFENIB(BAY43-9006) AND BLOOD PRESSURE$290,364

M01 · FY2006 · RR · contact PI

Clinical Therapeutics$196,140

T32 · FY2006 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$10,000

U01 · FY2006 · GM · contact PI

Pharmacogenetics of Anticancer Agents Research Group$3,000,870

U01 · FY2005 · GM

Phase I Clinical Trials of Anti-Cancer Agents$627,609

U01 · FY2005 · CA

Colorectal Cancer$371,488

U01 · FY2005 · GM

Administrative$332,713

U01 · FY2005 · GM

Clinical Therapeutics$196,140

T32 · FY2005 · GM

SORAFENIB(BAY43-9006) AND BLOOD PRESSURE$155,729

M01 · FY2005 · RR

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$25,000

U01 · FY2005 · GM

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$3,134,884

U01 · FY2004 · GM

Phase I Clinical Trials of Anti-Cancer Agents$615,693

U01 · FY2004 · CA

CLINICAL THERAPEUTICS$144,271

T32 · FY2004 · GM

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$13,125

U01 · FY2004 · GM

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$3,043,577

U01 · FY2003 · GM

Phase I Clinical Trials of Anti-Cancer Agents$584,507

U01 · FY2003 · CA

CLINICAL THERAPEUTICS$191,750

T32 · FY2003 · GM

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$2,867,250

U01 · FY2002 · GM

PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$517,996

U01 · FY2002 · CA

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$450,227

U01 · FY2002 · GM

GLUCURONIDATION (UGT) OF SN38--IRINOTECAN ACTIVITY$362,272

U01 · FY2002 · GM

GLUCURONIDATION (UGT) OF SN38--IRINOTECAN ACTIVITY$362,272

U01 · FY2002 · GM

CANCER AND LEUKEMIA GROUP B--PET COMMITTEE$233,136

U10 · FY2002 · CA

CLINICAL THERAPEUTICS$209,360

T32 · FY2002 · GM

PHASE I TRIAL OF ZD9331 AS 30 MIN INFUSION DAILY FOR 5 DAYS$0

M01 · FY2002 · RR

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM$0

P30 · FY2002 · CA

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM$0

P30 · FY2002 · CA

CORRELATING UGT1A1 GENOTYPE AND IRINOTECAN PHARMACOKINETICS IN CANCER PATIENTS$0

M01 · FY2002 · RR

OPTIMAL 06-BENZYLGUANINE DOSE FOR DNA ALKYLTRANSFERASE DEPLETION$0

M01 · FY2002 · RR

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$2,607,212

U01 · FY2001 · GM

PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$505,616

U01 · FY2001 · CA

GLUCURONIDATION (UGT) OF SN38--IRINOTECAN ACTIVITY$362,272

U01 · FY2001 · GM

CANCER AND LEUKEMIA GROUP B--PET COMMITTEE$181,507

U10 · FY2001 · CA

CLINICAL THERAPEUTICS$169,893

T32 · FY2001 · GM

CLINICAL THERAPEUTICS$56,093

T32 · FY2001 · GM

CLINICAL AND EXPERIMENTAL THERAPEUTICS$0

P30 · FY2001 · CA

CORE--PHARMACOLOGY FACILITY$0

P30 · FY2001 · CA

CORE--PHARMACOLOGY FACILITY$0

P30 · FY2001 · CA

CLINICAL AND EXPERIMENTAL THERAPEUTICS$0

P30 · FY2001 · CA

PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP$2,535,904

U01 · FY2000 · GM

PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS$577,193

U01 · FY2000 · CA

GLUCURONIDATION (UGT) OF SN38--IRINOTECAN ACTIVITY$362,272

U01 · FY2000 · GM

CLINICAL AND EXPERIMENTAL THERAPEUTICS$289,716

P30 · FY2000 · CA

CORE--PHARMACOLOGY FACILITY$289,716

P30 · FY2000 · CA

CANCER AND LEUKEMIA GROUP B--PET COMMITTEE$176,219

U10 · FY2000 · CA

CLINICAL THERAPEUTICS$159,810

T32 · FY2000 · GM

PHASE I TRIAL OF ZD9331 AS 30 MIN INFUSION DAILY FOR 5 DAYS$0

M01 · FY2000 · RR

CORRELATING UGT1A1 GENOTYPE AND IRINOTECAN PHARMACOKINETICS IN CANCER PATIENTS$0

M01 · FY2000 · RR

CORRELATING UGT1A1 GENOTYPE AND IRINOTECAN PHARMACOKINETICS IN CANCER PATIENTS$0

M01 · FY2000 · RR

OPTIMAL 06-BENZYLGUANINE DOSE FOR DNA ALKYLTRANSFERASE DEPLETION$0

M01 · FY2000 · RR

OPTIMAL 06-BENZYLGUANINE DOSE FOR DNA ALKYLTRANSFERASE DEPLETION$0

M01 · FY2000 · RR

PHASE I TRIAL OF ZD9331 AS 30 MIN INFUSION DAILY FOR 5 DAYS$0

M01 · FY2000 · RR